IMATINIB NEAPOLIS 100 MG BT 30

Treatment of adult and pediatric patients suffering from chronic Ph+ myeloid leukemia (CML) in the chronic phase, accelerated phase, as well as the blast crisis phase. Treatment of adult and pediatric patients with Ph+ acute lymphoblastic leukemia ((ALL Ph+) in combination with standard chemotherapy.

Treatment of adult patients with hypereosinophilic syndrome (HES), atypical myelodysplastic/myeloproliferative diseases (MDS/MPD) or an aggressive subtype of systemic mastocytosis (SM) associated with eosinophilia and either a mutation in the platelet-derived growth factor receptor (PDGF) alpha or beta, or a FIP1L1-PDGF-alpha fusion protein. Treatment of non-resectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) in adults.

Adjuvant treatment in adults at significant risk of recurrence after resection of c-Kit (CD 117) positive GIST: patients at low risk of recurrence should not receive adjuvant treatment.

Treatment of adults with non-resectable, recurrent or metastatic dermatofibrosarcoma protuberans (DFSP).